8-K Announcements
6Material company update
Feb 13, 2026·SEC
Material company update
Feb 13, 2026·SEC
Material company update
Jan 27, 2026·SEC
ProPhase Labs, Inc.(PRPH)Earnings, Financials & Key Ratios
PRPH•NASDAQ
$0.08
Price updated Jul 7, 2026
AboutProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Show more
- Revenue$4M-35.8%
- EBITDA-$13M+59.4%
- Net Income-$15M+72.4%
- EPS (Diluted)-1.74+93.3%
- Gross Margin31.85%+1537.6%
- EBITDA Margin-298.92%+36.7%
- Operating Margin-415.35%+27.2%
- Net Margin-339.31%+57.0%
- ROE-271.49%-44.3%
PRPH Price & Volume
ProPhase Labs, Inc. (PRPH) stock price & volume — 10-year historical chart
Loading chart...
Severe Liquidity Constraints Threaten Operational Viability
Investment Thesis • Updated 2025Q4
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and insolvency
Key Thesis Takeaways
- ProPhase Labs faces a critical inflection point as it struggles to transition from its post-pandemic diagnostic revenue base, evidenced by a persistent revenue decline and recurring net losses.
- The company's financial stability is severely compromised by a precarious cash position of only $90,000 and a debt-to-equity ratio that has surged to 2.46.
- Investors should remain cautious as the firm's inability to scale SG&A expenses, which remain disproportionately high, suggests significant insolvency risks that may necessitate further dilutive financing.
Verdict Logic
the company's immediate liquidity risk is underscored by a cash balance of only $90,000 against a current ratio of 0.06, signaling an imminent threat to operational continuity.
PRPH Growth Metrics
ProPhase Labs, Inc. (PRPH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-14.41%
5 Years-21.43%
3 Years-67.16%
TTM-25.73%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM44.21%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM80.49%
Return on Capital
10 Years-25.43%
5 Years-29.8%
3 Years-67.1%
Last Year-95.35%
PRPH Recent Earnings
ProPhase Labs, Inc. (PRPH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (64%)●Beat Revenue 0/12 qtrs (0%)
Q3 2026Latest
Jun 30, 2026Metric
Actual
Est
EPS
$0.43
—
Rev
$478,000
—
Q3 2026
Jun 24, 2026Metric
Actual
Est
EPS
$0.87+27.5%
$1.20
Rev
$784,000-91.9%
$10M
Q3 2026
Jun 22, 2026Metric
Actual
Est
EPS
$0.87+27.5%
$1.20
Rev
$784,000-91.9%
$10M
Q3 2026
Jun 16, 2026Metric
Actual
Est
EPS
$0.87+27.5%
$1.20
Rev
$784,000-91.9%
$10M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 30, 2026 | $0.43 | $478,000 |
| Q3 2026 | Jun 24, 2026 | $0.87vs $1.20+27.5% | $784,000vs $10M-91.9% |
| Q3 2026 | Jun 22, 2026 | $0.87vs $1.20+27.5% | $784,000vs $10M-91.9% |
| Q3 2026 | Jun 16, 2026 | $0.87vs $1.20+27.5% | $784,000vs $10M-91.9% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for ProPhase Labs, Inc. (PRPH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.08 | $360.49K | -0.04 | -35.82% | -339.31% | -271.49% | — | |
| $17.00 | $1.16B | -1.02 | -1.89% | -45.57% | -56.31% | — | |
| $5.00 | $2.59B | -29.41 | 40.34% | -2.58% | -17.08% | — | |
| $1.14 | $3.74M | -0.24 | -7.37% | -109.95% | -71.38% | — | |
| $281.27 | $40.28B | -185.05 | 35.9% | -9.05% | -15.13% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — |
Compare PRPH vs Peers
ProPhase Labs, Inc. (PRPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PRPH SEC Filings & Documents
ProPhase Labs, Inc. (PRPH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when PRPH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PRPH Frequently Asked Questions
ProPhase Labs, Inc. (PRPH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is ProPhase Labs, Inc.'s revenue?
ProPhase Labs, Inc. (PRPH) reported $3.4M in revenue for fiscal year 2025. This represents a 324% increase from $0.8M in 1996.
How fast is ProPhase Labs, Inc. growing?
ProPhase Labs, Inc. (PRPH) saw revenue decline by 35.8% over the past year.
Is PRPH profitable?
ProPhase Labs, Inc. (PRPH) reported a net loss of $24.1M for fiscal year 2025.
Dividend & Returns
What is PRPH's return on equity?
ProPhase Labs, Inc. (PRPH) has a return on equity (ROE) of -271.5%. Negative ROE indicates the company is unprofitable.
What is ProPhase Labs, Inc.'s free cash flow?
ProPhase Labs, Inc. (PRPH) had negative free cash flow of $30.9M in fiscal year 2025, likely due to heavy capital investments.